Clinical Oncology Next Generation Sequencing Market

Next?generation?sequencing?(NGS) has created a noteworthy paradigm shift in the clinical diagnostic field. It refers to an aggregate collection of methods in which various?sequencing?reactions occur at the same time, bringing about vast amounts of?sequencing?data for a little division of the cost of Sanger?sequencing.

Clinical Oncology Next Generation Sequencing Market contains market size and forecasts of Clinical Oncology Next Generation Sequencing in Global, including the following market information:

Global Clinical Oncology Next Generation Sequencing Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Clinical Oncology Next Generation Sequencing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Whole Genome Sequencing Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Clinical Oncology Next Generation Sequencing include Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine and Pacific Bioscience, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Clinical Oncology Next Generation Sequencing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Clinical Oncology Next Generation Sequencing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Clinical Oncology Next Generation Sequencing Market Segment Percentages, by Type, 2021 (%)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

Global Clinical Oncology Next Generation Sequencing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Clinical Oncology Next Generation Sequencing Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Laboratories

Global Clinical Oncology Next Generation Sequencing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Clinical Oncology Next Generation Sequencing Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Clinical Oncology Next Generation Sequencing revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Clinical Oncology Next Generation Sequencing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Illumina, Inc.

Thermo Fisher Scientific

F. Hoffmann-La Roche Ltd.

Agilent Technologies

Myriad Genetics

Beijing Genomics Institute (BGI)

Perkin Elmer

Foundation Medicine

Pacific Bioscience

Oxford Nanopore Technologies Ltd.

Paradigm Diagnostics

Caris Life Sciences

Partek, Inc.

Eurofins Scientific S.E.

Qiagen N.V.